This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
When your budget is failing, prioritize essential expenses, cut non-essentials, and reallocate funds. This guide offers practical steps to regain control.
16,732 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A seasoned CEO message can move markets, especially in AI era. This deep dive explains what broadcom hock just delive...
A sharp 20% plunge in Circle tokens sparked by yield shifts under a new Clarity Act framework. This morning minute re...
This week brought a sharp decline in lenz therapeutics stock plummeted as concerns about revenue growth and financing...
Take a practical tour of arcutis (arqt) 2026 earnings, from revenue mix and margins to pipeline progress and risk fac...
A growing number of high-income workers are using in-plan roth conversion high strategies within 401(K) plans to dodg...
Broadcom is shifting from a broad tech portfolio to a focused AI chip powerhouse. If the company can turn custom AI c...
Investors are weighing value exposure against high-quality income. This piece analyzes why SCHD may outperform VTV on...
The AI boom isn’t just about memory chips anymore. A broader wave of demand is lifting compute, software, and data in...
P3 Health is shaping the future of value-based care with its platform. This guide breaks down what to expect from hea...
A February market shock erased roughly $285B in software valuations, forcing a rethink of what truly drives software ...
Explore the highlights from the (rlx) 2026 earnings call, including what drove revenue, how margins are shaping up, a...